search
Back to results

Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis

Primary Purpose

Acute Bronchitis

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Acebrophylline
Sponsored by
Hyundai Pharmaceutical Co., LTD.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Bronchitis

Eligibility Criteria

19 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female aged 19 to 65 years, inclusive
  2. Patients with acute bronchitis which is accompanied with a cough which includes sputum within 48 hours and has over 5 for Bronchitis severity score (BSS) at Screening
  3. Patients who agreed to participate clinical trial and sign on informed consent form

Exclusion Criteria:

  1. Patients who are suspicious or diagnosed for pneumonia
  2. Patients with chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD), bronchiolitis, asthma, bronchial asthma
  3. Patients with active infection who needs administration of antibiotics
  4. Patients with myocardial infarction, congestive heart failure
  5. Patients with renal disorder or liver disorder
  6. Patients with hypotension or hypertension
  7. Patients with history of epilepsy
  8. Patients with hyperthyroidism
  9. Patients with gastroduodenal ulcer
  10. Patients with sever hypoxemia
  11. Patients who are in drug or therapy or planned to have;

    • antibiotics, anti-virus, angiotensin converting enzyme (ACE) inhibitor and systemic or inhalation glucocorticosteroids: from 2 weeks prior to administration of investigational product to termination of clinical trial
    • Angiotension II receptor blocker (ARB), secretolytics/mucolytics, expectorants, antitussives, a herb medicines which has antitussive or expectorant effect: from 2 days prior to administration of investigational product to termination of clinical trial
    • Analgesics except acetaminophen, antihistamines, β2-agonists, bronchodilators which includes anticholinergic agents, xanthine derivatives, central nervous system stimulants, drug which is known for interaction between acebrophylline (cimetidine, alloprinol, oral anticoagulants, furosemide, reserpine, barbiturates, phenytoin) and symtomatic therapy for other therapy for acute bronchitis: whole period for clinical trial
  12. Smokers
  13. Patients who has history for drug hypersensitivity or allergic reaction in component of investigational product or similar drug
  14. Patients with pregnant and/or have breast feeding.
  15. Patients with no intention to use appropriate contraceptives or has a plan to become pregnant
  16. Patients who had an administrationb of other investigational product or medical device for clinical trial 4 weeks prior to participation of clinical trial
  17. Patients who are identified as inappropriate by other investigators to participate clinical trial

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Sulfolase CR (200mg, QD)

    Sulfolase Capsule (100mg, BID)

    Arm Description

    for 7 days with or without meal

    for 7 days with or without meal

    Outcomes

    Primary Outcome Measures

    Change from Baseline in baseline to Day 7 for total number of Bronchitis Severity Score (BSS)

    Secondary Outcome Measures

    Change from Baseline in baseline to Day 7 for number of BSS per symptom
    Response rate at Day 7

    Full Information

    First Posted
    June 3, 2016
    Last Updated
    June 15, 2017
    Sponsor
    Hyundai Pharmaceutical Co., LTD.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02792946
    Brief Title
    Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2015 (Actual)
    Primary Completion Date
    January 2016 (Actual)
    Study Completion Date
    January 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hyundai Pharmaceutical Co., LTD.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Compare the efficacy and safety of surfolase CR tablet with surfolate capsule in patients with acute bronchitis

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Acute Bronchitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    244 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Sulfolase CR (200mg, QD)
    Arm Type
    Experimental
    Arm Description
    for 7 days with or without meal
    Arm Title
    Sulfolase Capsule (100mg, BID)
    Arm Type
    Active Comparator
    Arm Description
    for 7 days with or without meal
    Intervention Type
    Drug
    Intervention Name(s)
    Acebrophylline
    Primary Outcome Measure Information:
    Title
    Change from Baseline in baseline to Day 7 for total number of Bronchitis Severity Score (BSS)
    Time Frame
    Baseline, At Day 7
    Secondary Outcome Measure Information:
    Title
    Change from Baseline in baseline to Day 7 for number of BSS per symptom
    Time Frame
    Baseline, At Day 7
    Title
    Response rate at Day 7
    Time Frame
    Baseline, At Day 7

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female aged 19 to 65 years, inclusive Patients with acute bronchitis which is accompanied with a cough which includes sputum within 48 hours and has over 5 for Bronchitis severity score (BSS) at Screening Patients who agreed to participate clinical trial and sign on informed consent form Exclusion Criteria: Patients who are suspicious or diagnosed for pneumonia Patients with chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD), bronchiolitis, asthma, bronchial asthma Patients with active infection who needs administration of antibiotics Patients with myocardial infarction, congestive heart failure Patients with renal disorder or liver disorder Patients with hypotension or hypertension Patients with history of epilepsy Patients with hyperthyroidism Patients with gastroduodenal ulcer Patients with sever hypoxemia Patients who are in drug or therapy or planned to have; antibiotics, anti-virus, angiotensin converting enzyme (ACE) inhibitor and systemic or inhalation glucocorticosteroids: from 2 weeks prior to administration of investigational product to termination of clinical trial Angiotension II receptor blocker (ARB), secretolytics/mucolytics, expectorants, antitussives, a herb medicines which has antitussive or expectorant effect: from 2 days prior to administration of investigational product to termination of clinical trial Analgesics except acetaminophen, antihistamines, β2-agonists, bronchodilators which includes anticholinergic agents, xanthine derivatives, central nervous system stimulants, drug which is known for interaction between acebrophylline (cimetidine, alloprinol, oral anticoagulants, furosemide, reserpine, barbiturates, phenytoin) and symtomatic therapy for other therapy for acute bronchitis: whole period for clinical trial Smokers Patients who has history for drug hypersensitivity or allergic reaction in component of investigational product or similar drug Patients with pregnant and/or have breast feeding. Patients with no intention to use appropriate contraceptives or has a plan to become pregnant Patients who had an administrationb of other investigational product or medical device for clinical trial 4 weeks prior to participation of clinical trial Patients who are identified as inappropriate by other investigators to participate clinical trial

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis

    We'll reach out to this number within 24 hrs